Associated Papers
Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease.
Phillips IR et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain.
Teitelbaum AM et al.
The Pharmacogenomics Journal, 2018
Clinical utility gene card for: Trimethylaminuria - update 2014.
Shephard EA et al.
European Journal of Human Genetics : Ejhg, 2015
Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities.
Yamazaki H et al.
Biochemical Pharmacology, 2013
Trimethylaminuria: an under-recognised and socially debilitating metabolic disorder.
Christodoulou J
Journal of Paediatrics and Child Health, 2012
Clinical utility gene card for: trimethylaminuria.
Shephard EA et al.
European Journal of Human Genetics : Ejhg, 2012
Flavin-containing monooxygenases: mutations, disease and drug response.
Phillips IR et al.
Trends in Pharmacological Sciences, 2008
Flavin-containing monooxygenase 3 and human disease.
Motika MS et al.
Expert Opinion on Drug Metabolism & Toxicology, 2007
Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3).
Allerston CK et al.
Pharmacogenetics and Genomics, 2007
Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria.
Yeung CK et al.
Archives of Biochemistry and Biophysics, 2007
Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants.
Koukouritaki SB et al.
The Journal of Pharmacology and Experimental Therapeutics, 2007
Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants.
Koukouritaki SB et al.
Molecular Pharmacology, 2005